Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)

TIM, 2000 - triflusal vs aspirine

HIT-4, 1999 - Hirudin vs heparin

Klootwijk, 1999 - Efegatran vs heparin



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of warfarin
    		•  

    OASIS-2 Warfarin Substudy study, 2001

    Treatments

    Studied treatment warfarin target INR 2–2.5 for 5 months +aspirin
    Control treatment control
    Concomittant treatment aspirin Standard dose

    Patients

    Patients UA

    Method and design

    Randomized effectives 1848 / 1864 (studied vs. control)
    Blinding open
    Follow-up duration 5 months
    Lost to follow-up 0.4%


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    all cause death, non-fatal MI, thrombo-embolic stroke

    140 / 1848
         155 / 1864
         0,91 [0,73;1,13]

    Major bleeding

    49 / 1848
         25 / 1864
         classic 1,98 [1,23;3,19]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    all cause death, non-fatal MI, thrombo-embolic stroke 140 / 1848 (7,6%) 155 / 1864 (8,3%) 0,91 [0,73;1,13]   8504 
    Major bleeding 49 / 1848 (2,7%) 25 / 1864 (1,3%) 1,98 [1,23;3,19]   8504 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 8504: Andreotti F, Testa L, Biondi-Zoccai GG, Crea FAspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.Eur Heart J 2006;27:519-26
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    all cause death, non-fatal MI, thrombo-embolic stroke 7,58% 8,32% -7,4‰
    Major bleeding 2,65% 1,34% 1,3%


    Reference(s)

    Trials register # NA
    • . Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.. J Am Coll Cardiol 2001;37:475-84
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend